Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
Status:
Terminated
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to deliver proof of concept that antifungal prophylaxis can
reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit)
patients with severe influenza.
The investigators will perform an interventional non-blinded randomized controlled
multicentric proof-of-concept study in patients with severe influenza admitted to the ICU.
Patients will be randomized to the posaconazole prophylaxis group or to the SOC (standard of
care) group. Oseltamivir will be started at the discretion of the investigator. Patients in
the posaconazole group will receive posaconazole prophylaxis for 7 days.
addendum: pharmacokinetics of posaconazole as prophylaxis for invasive fungal disease on ICU